Matt Gline, Roivant CEO (courtesy Roivant)
Roivant CEO hints at more deals shaping up as key Immunovant data loom
Roivant Sciences has more potential asset deals in the works — after setting up two Vants around Pfizer assets in the past two years — and hopes …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
